20.95 +0.17 (0.82%)
Pre-Market: 7:31AM EDT
|Bid||0.00 x 900|
|Ask||20.95 x 3000|
|Day's Range||19.86 - 20.91|
|52 Week Range||17.89 - 52.74|
|Beta (3Y Monthly)||3.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) ranks number one on the TSX 30. However, the marquee pot stock is not a great buy today.
Aphria (APHA) reported impressive results for the first quarter of fiscal 2020 on Tuesday. The stock has gained 9.6% since its earnings.
Pineapple Express actor Seth Rogen founds cannabis brand, Houseplant, with Evan Goldberg and teams up with Canopy Growth (TSX:WEED)(NYSE:CGC).
As of Tuesday, Charlotte’s Web Holdings was trading at 18.15 Canadian dollars, which implies a fall of 37.0% since its second-quarter earnings on August 14.
TORONTO, Oct. 16, 2019 /CNW/ -- Houseplant has introduced Pre-Rolled Joints and Softgel Capsules to its growing list of product offerings, which also includes a full offering of Sativa, Indica and Hybrid Flower. Co-founded by Seth Rogen and Evan Goldberg in partnership with Canopy Growth Corporation, Houseplant continues to fulfill its promise of supplying the highest quality cannabis products to consumers.
Aphria (TSX:APHA)(NYSE:APHA) stock jumped nicely by about 20% this morning after reporting its second profitable earnings this morning.
Mexico is fast approaching its October 23 marijuana legalization deadline. Multiple legalization proposals before parliament are creating confusion.
Canopy Growth (TSX:WEED)(NYSE:CGC) is increasingly looking like a reasonable investment for long-term contrarians willing to take the risk.
Should marijuana investors buy Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) on the dip after losing 65% of its value? Or is the stock going to shed another 75%?
SMITHS FALLS, ON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX:WEED.TO - News) (NYSE:CGC - News) ("Canopy Growth") has sold its 42,087,639 shares in Australian cannabis company AusCann Group Holdings (AusCann) via an off market block trade at $0.15 per share for gross proceeds of $6.3 million. The sale represents Canopy Growth's total 13.2% interest in AusCann. "Canopy Growth remains optimistic about the future of the Australian medical cannabis market and will continue to collaborate with the team at Auscann to support greater physician understanding and patient access to high quality cannabis products throughout Australia," said Mark Zekulin, CEO, Canopy Growth.
SMITHS FALLS, ON & LONDON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX:WEED.TO - News) (NYSE:CGC - News) ("Canopy Growth" or the "Company") has closed the previously announced acquisition of all outstanding shares in the global cannabinoid based research company Beckley Canopy Therapeutics (Beckley Canopy), including the joint commercial venture Spectrum Biomedical UK. As a part of the acquisition, Canopy Growth's European management structure will evolve. Paul Steckler and Steven Wooding will assume the roles of Co-Managing Directors in charge of all European operations.